BIAXIN XL
LOE ApproachingNDAORALTABLET
Approved
Dec 1993
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 9h ago · AI intelligence enriched Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BIAXIN XL is a brand-name oral tablet formulation approved in 1993 for bacterial infections. The product is a small-molecule antibiotic in the macrolide class. Generic equivalents are likely available or approaching market entry.
LOE Approaching
As a maturing branded antibiotic facing LOE, teams are typically smaller and focused on managed care retention and cost-defense strategies rather than growth expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
BIAXIN XL offers limited career growth opportunity due to LOE approaching status and minimal linked job postings. Roles emphasize defending market position, managing reimbursement erosion, and ensuring regulatory compliance rather than innovation or expansion.
Brand ManagerMedical Science Liaison (MSL)
Worked on BIAXIN XL at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.